ACTON, Mass. - Insulet (NASDAQ:PODD) Corporation (NASDAQ: PODD), a leading provider of tubeless insulin pump technology, reported a significant beat in its fourth-quarter earnings, surpassing analyst expectations.
Despite this, shares fell by 7% due to the company's softer guidance for the upcoming periods.
For the fourth quarter, Insulet reported adjusted earnings per share (EPS) of $1.40, which was $0.75 higher than the analyst consensus of $0.65. Revenue for the quarter was equally strong, coming in at $509.8 million, notably higher than the consensus estimate of $461.26 million. This performance represents a substantial increase of 37.9% compared to the same period last year, with constant currency revenue growth of 36.6%.
The company highlighted its eighth consecutive year of more than 20% constant currency revenue growth, a testament to the strong demand for its Omnipod products. U.S. Omnipod revenue alone surged by 42.9% year-over-year (YoY), while the international segment saw an 18.0% increase, or 12.5% in constant currency.
However, investor sentiment was dampened by the company's forward-looking statements. Insulet provided guidance for the first quarter and full year of 2024, which includes an expected revenue growth range of 12% to 17% for the full year and 17% to 20% for the first quarter. This outlook considers an estimated $20 million to $25 million in revenue that was accelerated into the fourth quarter of 2023 from the first quarter of 2024 due to the implementation of a new ERP system.
President and CEO Jim Hollingshead commented on the year's success, stating, "2023 was another transformational year for Insulet. The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue growth." He also expressed confidence in the company's continued profitable growth and value creation.
Despite the positive results, the softer guidance for the upcoming year has led to a negative market response, with the stock price reflecting investor concerns about future growth prospects.
Insulet's financial strength was further evidenced by a gross margin of 70.9% for the quarter, up significantly from the previous year, and an adjusted operating income of $105.5 million, or 20.7% of revenue. The company's net income for the quarter stood at $103.3 million, or $1.44 per diluted share, compared to $17.0 million, or $0.24 per diluted share, in the prior year.
Investors will be watching closely to see if Insulet can maintain its growth trajectory in the face of the guidance provided and broader market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.